Literature DB >> 29710505

Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.

Mohammad Hasan Soheilifar1, Ramezan Ali Taheri2, Reza Zolfaghari Emameh3, Abdolvahab Moshtaghian4, Hamid Kooshki5, Mohammad Reza Motie6.   

Abstract

Alveolar soft part sarcoma (ASPS) is a highly aggressive rare soft tissue sarcoma (STS) with poor prognosis especially in the metastatic form. ASPS is resistant to standard chemotherapy. Although, early diagnosis and surgical resection of operable tumor could lead to improved patient survival but novel treatment options are needed for advanced (metastatic) ASPS. This malignancy exhibits highly angiogenic behavior which reflects hyper-activation and over expression of angiogenic factors. Understanding the molecular events in this type of sarcoma is important in finding novel molecular based targeted therapies. We aim to review molecular aspects of ASPS growth and treatment.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alveolar soft part sarcoma; Drug resistance; Molecular targeted therapy; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2018        PMID: 29710505     DOI: 10.1016/j.biopha.2018.04.117

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

Review 1.  The current management of alveolar soft part sarcomas.

Authors:  Xiaojing Chang; Yuehong Li; Xiaoying Xue; Huandi Zhou; Liubing Hou
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

2.  Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.

Authors:  Hui Su; Chao Yu; Xuezhen Ma; Qingcui Song
Journal:  Invest New Drugs       Date:  2021-03-25       Impact factor: 3.850

Review 3.  Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.

Authors:  Jin Yuan; Xiaoyang Li; Shengji Yu
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

Review 4.  Angioregulatory microRNAs in Colorectal Cancer.

Authors:  Mohammad Hasan Soheilifar; Michael Grusch; Hoda Keshmiri Neghab; Razieh Amini; Hamid Maadi; Massoud Saidijam; Zhixiang Wang
Journal:  Cancers (Basel)       Date:  2019-12-26       Impact factor: 6.639

Review 5.  Chemotherapy: a double-edged sword in cancer treatment.

Authors:  Nafiseh Behranvand; Farzad Nasri; Reza Zolfaghari Emameh; Pouria Khani; Asieh Hosseini; Johan Garssen; Reza Falak
Journal:  Cancer Immunol Immunother       Date:  2021-08-05       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.